Bucladesine

Bucladesine
Systematic (IUPAC) name

sodium (3aR,4R,6R,6aR)-4-(6-butanamido-9H-purin-9-yl)-6-[(butanoyloxy)methyl]-2-oxo-tetrahydro-2H-1,3,5,2λ⁵-furo[3,4-d][1,3,2]dioxaphosphol-2-olate
Clinical data
AHFS/Drugs.com	International Drug Names
Identifiers
CAS Number	362-74-3^Y
ATC code	C01CE04
PubChem	CID 28177
IUPHAR/BPS	5485
ChemSpider	9306^Y
UNII	63X7MBT2LQ^Y
ChEBI	CHEBI:50095^Y
ChEMBL	CHEMBL485980^Y
Synonyms	• Dibutyryl cyclic adenosine monophosphate • (N6,2'-O-dibutyryl)-adenosine-3',5'-mono-phosphate • Dibutyryl cAMP • DcAMP • DBcAMP
Chemical data
Formula	C₁₈H₂₃N₅NaO₈P
Molar mass	491.368 g/mol
SMILES O=C(Nc4ncnc1c4ncn1[C@@H]2O[C@@H]3COP(=O)(O[C@H]3[C@H]2OC(=O)CCC)O)CCC
InChI InChI=1S/C18H24N5O8P/c1-3-5-11(24)22-16-13-17(20-8-19-16)23(9-21-13)18-15(30-12(25)6-4-2)14-10(29-18)7-28-32(26,27)31-14/h8-10,14-15,18H,3-7H2,1-2H3,(H,26,27)(H,19,20,22,24)/t10-,14-,15-,18-/m1/s1^Y Key:CJGYSWNGNKCJSB-YVLZZHOMSA-N^Y
(verify)

Bucladesine is a cyclic nucleotide derivative which mimics the action of endogenous cAMP and is a phosphodiesterase inhibitor.

Bucladesine is a cell permeable cAMP analog. The compound is used in a wide variety of research applications because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions. cAMP is only able to elicit minimal responses in these situations.

The neurite outgrowth instigated by bucladesine in cell cultures has been shown to be enhanced by nardosinone.

External links

Bucladesine at the US National Library of Medicine Medical Subject Headings (MeSH)

PDE inhibitors

PDE1	MMPX SCH-51866 Vinpocetine

PDE2	BAY 60-7550 EHNA Oxindole PDP

PDE3	Adibendan Amrinone (inamrinone) Anagrelide Bucladesine Cilostamide Cilostazol Enoximone Imazodan KMUP-1 Meribendan Milrinone Olprinone Pimobendan Quazinone RPL-554 Siguazodan Tetomilast Tofimilast Trequinsin Vesnarinone

PDE4	AN2728 Apremilast Arofylline Atizoram Catramilast CC-1088 CDP-840 CGH-2466 Cilomilast Cipamfylline CP-80633 Crisaborole Denbutylline Drotaverine Etazolate Filaminast Glaucine HT-0712 ICI-63197 Indimilast Irsogladine Lavamilast Lirimilast Luteolin Mesembrenone Mesembrine Mesopram Oglemilast Piclamilast Revamilast Ro 20-1724 Roflumilast Rolipram Ronomilast RPL-554 RS-25344 YM-976

PDE5	Acetildenafil Aildenafil Avanafil Beminafil Benzamidenafil Dasantafil Icariin Gisadenafil Homosildenafil Lodenafil Mirodenafil MY-5445 Nitrosoprodenafil Sildenafil Sulfoaildenafil T-0156 Tadalafil Udenafil Vardenafil

PDE7	BRL-50481

PDE9	BAY 73-6691 PF-04447943

PDE10	Papaverine PF-2545920 TC-E 5005 Tofisopam

PDE11	BC11-38

Nonselective	Aminophylline Caffeine Choline theophyllinate CPX Dipyridamole Doxofylline Enprofylline Ibudilast IBMX Luteolin Paraxanthine Pentoxifylline Propentofylline SCH-51866 Theobromine Theophylline Zaprinast Zardaverine

Unknown/unsorted	Benafentrine Carbazeran Diazepam Diphylline Doxofylline DPCPX Furafylline Lisofylline MDL-12330A Moxaverine Oxagrelate Parogrelil Pentifylline Proxyphylline Pumafentrine Quercetin Tolafentrine Trapidil

Cardiac stimulants excluding cardiac glycosides (C01C)

Adrenergic and
dopaminergic agents

Adrenergic agonists

α	Metaraminol Phenylephrine Methoxamine Norfenefrine Oxedrine Midodrine Mephentermine

β	Dobutamine Arbutamine Isoprenaline Prenalterol

mixed	Amezinium metilsulfate Droxidopa Epinephrine # Norepinephrine Etilefrine

Dopamine agonists

Fenoldopam

Both

Unknown/ungrouped

Phosphodiesterase inhibitors (PDE3I)

Other cardiac stimulants

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Tuesday, January 26, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.